Loading...
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous therapies received Bendamustine (90 mg/m(2), day 1 + 2) and...
Na minha lista:
| Udgivet i: | Hemasphere |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wolters Kluwer Health
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7306311/ https://ncbi.nlm.nih.gov/pubmed/32647802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000398 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|